NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences Inc (NYSE:RCUS) released its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. The firm had revenue of $1.75 million for the quarter, compared to analyst estimates of $1.34 million. Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. View Arcus Biosciences' Earnings History.

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

5 equities research analysts have issued 1-year price objectives for Arcus Biosciences' stock. Their forecasts range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' stock price to reach $19.25 in the next year. This suggests a possible upside of 147.1% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

Headlines about RCUS stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcus Biosciences earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the company's share price in the immediate future. View News Stories for Arcus Biosciences.

Arcus Biosciences saw a decrease in short interest in November. As of November 15th, there was short interest totalling 1,590,000 shares, a decrease of 20.9% from the October 31st total of 2,010,000 shares. Based on an average daily trading volume, of 245,600 shares, the days-to-cover ratio is currently 6.5 days. Currently, 5.8% of the company's stock are sold short. View Arcus Biosciences' Current Options Chain.

Some companies that are related to Arcus Biosciences include Epizyme (EPZM), Axsome Therapeutics (AXSM), Esperion Therapeutics (ESPR), Innoviva (INVA), Y-mAbs Therapeutics (YMAB), Arvinas (ARVN), Athenex (ATNX), Enanta Pharmaceuticals (ENTA), Wave Life Sciences (WVE), BELLUS Health (BLUSF), Theravance Biopharma (TBPH), Principia Biopharma (PRNB), Supernus Pharmaceuticals (SUPN), Endo International (ENDP) and ArQule (ARQL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), Fate Therapeutics (FATE), Vale (VALE), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), BIOLINERX LTD/S (BLRX), Cidara Therapeutics (CDTX) and Exelixis (EXEL).

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.35%), Millennium Management LLC (0.41%), Parallel Advisors LLC (0.19%), California State Teachers Retirement System (0.11%), Rhumbline Advisers (0.11%) and Barclays PLC (0.05%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.

RCUS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Bailard Inc.. View Insider Buying and Selling for Arcus Biosciences.

RCUS stock was acquired by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, Millennium Management LLC, State Street Corp, California Public Employees Retirement System, Russell Investments Group Ltd., Rhumbline Advisers, Meeder Asset Management Inc. and California State Teachers Retirement System. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $7.79.

Arcus Biosciences has a market capitalization of $357.24 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

The official website for Arcus Biosciences is http://www.arcusbio.com/.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]